Cytokinetics (CYTK) EBITDA (2010 - 2026)
Cytokinetics (CYTK) posted quarterly EBITDA of -$183.6 million for Q1 2026, down 17.98% year-over-year from -$223.9 million in Q1 2025, and down 2.94% quarter-over-quarter from -$178.4 million in Q4 2025.
Cytokinetics (CYTK) EBITDA (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported EBITDA for 17 consecutive years, with -$183.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 17.98% year-over-year to -$183.6 million; the TTM figure through Mar 2026 stood at -$640.2 million (down 13.19% YoY), while the FY2025 annual figure was -$612.3 million, down 14.17% from the prior year.
- EBITDA eased to -$183.6 million in Q1 2026 per CYTK's latest filing, from -$178.4 million in the prior quarter.
- Across five years, EBITDA topped out at -$10.9 million in Q2 2022 and bottomed at -$183.6 million in Q1 2026.
- Historically, EBITDA has averaged -$126.6 million across 5 years, with a median of -$127.0 million in 2022.
- Annual changes were most pronounced in 2022 — EBITDA soared 80.16% — and 2023, when it slumped 1022.39%.
- Cytokinetics' EBITDA stood at -$127.0 million in 2022, then slipped by 0.31% to -$127.4 million in 2023, then declined by 9.12% to -$139.0 million in 2024, then retreated by 28.28% to -$178.4 million in 2025, then retreated by 2.94% to -$183.6 million in 2026.
- Business Quant data shows CYTK's EBITDA at -$183.6 million in Q1 2026, -$178.4 million in Q4 2025, and -$166.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | -179.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -179.17 Mn |
| Mar 31, 2026 | -183.62 Mn |
| Dec 31, 2025 | -178.37 Mn |
| Sep 30, 2025 | -166.76 Mn |
| Jun 30, 2025 | -111.51 Mn |
| Mar 31, 2025 | -155.63 Mn |
| Dec 31, 2024 | -139.04 Mn |
| Sep 30, 2024 | -140.80 Mn |
| Jun 30, 2024 | -130.17 Mn |
| Mar 31, 2024 | -126.24 Mn |
| Dec 31, 2023 | -127.42 Mn |
| Sep 30, 2023 | -122.27 Mn |
| Jun 30, 2023 | -122.05 Mn |
| Mar 31, 2023 | -124.47 Mn |
| Dec 31, 2022 | -127.03 Mn |
| Sep 30, 2022 | -108.44 Mn |
| Jun 30, 2022 | -10.87 Mn |
| Mar 31, 2022 | -77.86 Mn |
| Dec 31, 2021 | -21.70 Mn |
| Sep 30, 2021 | -69.20 Mn |